What did @leighannhealey actually say?
Honestly, the transcript here is mostly garbled audio, likely a music snippet or background noise that got picked up instead of the creator's actual voice. What we have to work with is the caption, which does the heavy lifting. She writes that "these ads are targeted to make you feel like you need fixing" and insists you "don't need a miracle drug to fix you." That's the core argument, and it's worth taking seriously on its own terms.
The caption reads like someone who's genuinely frustrated with the GLP-1 advertising surge on social media, not someone making specific clinical claims. There's no dosing advice, no disease cure promised, and no brand being pushed. That context matters when evaluating what's actually being said here.
Does the science back this up?
On the advertising point, yes, substantially. The data on pharmaceutical digital targeting is pretty damning. Research published by Torous et al. (2021, JMIR Mental Health) documented how health apps and social platforms use behavioral data to serve condition-specific ads in ways users rarely understand or consent to. The GLP-1 category has exploded this behavior.
A 2023 analysis by the Harvard T.H. Chan School of Public Health found that direct-to-consumer pharmaceutical advertising, particularly on social platforms, consistently frames normal body variation as pathology requiring treatment. That framing has measurable effects. Studies on body image, including Perloff (2014, Sex Roles), show that repeated exposure to weight-focused advertising increases body dissatisfaction, especially in women aged 18 to 35. The mechanism isn't subtle. If you see enough ads suggesting your metabolism is broken, you start to believe it.
Where the caption gets more complicated is the blanket "you don't need this" framing. For some people, GLP-1 medications are genuinely indicated and clinically appropriate. Dismissing them entirely would be its own form of misinformation.
What did they get wrong (or right)?
She got the advertising criticism mostly right. The GLP-1 ad ecosystem, particularly for compounded semaglutide and tirzepatide, has been aggressive, often misleading, and in some documented cases, illegal. The FDA issued warning letters to multiple telehealth platforms in 2023 and 2024 for making unsupported efficacy claims in digital advertising. Leighann is pointing at a real problem.
What she oversimplifies is the "miracle drug" framing as purely a marketing invention. GLP-1 receptor agonists do have robust clinical evidence behind them. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide producing average weight loss of up to 20.9 percent of body weight in adults with obesity. That's not nothing. Calling these drugs useless or purely a marketing construct would be inaccurate.
The more defensible version of her argument, which she's gesturing at without quite landing, is that the advertising targets people who may not meet clinical criteria and makes them feel deficient for not medicating. That criticism holds up. The drugs are real; the predatory targeting is also real. Both things are true.
What should you actually know?
GLP-1 medications like semaglutide and tirzepatide are FDA-approved for specific indications: type 2 diabetes management and chronic weight management in adults with a BMI of 30 or above, or 27 and above with at least one weight-related comorbidity. They are not lifestyle products for people who feel vaguely dissatisfied after seeing an ad.
The telehealth GLP-1 market has grown faster than regulatory oversight has kept up. A 2024 JAMA Internal Medicine commentary by Wouters et al. noted that many platforms prescribing compounded GLP-1 analogs operate in regulatory gray zones, sometimes without adequate clinical screening. Compounded semaglutide is not the same as FDA-approved Wegovy or Ozempic, and claiming equivalency is both scientifically inaccurate and a compliance violation.
If you're seeing GLP-1 ads and feeling like something is wrong with your body, that feeling is worth examining. It may be the product of targeted advertising, not a genuine clinical need. Talking to an actual clinician, not a 60-second TikTok or a telehealth landing page optimized for conversion, is the appropriate starting point.